secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytosorbents Corp (CTSO)
CIK:        0001175151
Form:       8-K
Filed at:   2022-04-05T23:59:59+00:00
Accession:  0001104659-22-042785
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytoSorbents appoints Jiny Kim to Board of Directors as independent director
----------------------------------------------------------------------------

- Appointment effective April 1, 2022; term expires at June 7, 2022 annual meeting, where she is expected to stand for re-election.
- Board expanded from five to six members; Kim brings medical device experience from Zimmer Biomet, LivaNova, and Johnson & Johnson.
- Kim currently VP at Zimmer Biomet leading Smart Implants portfolio, including launch of Persona IQ® smart knee implant.
- She will receive standard non-employee director compensation; committee assignments not yet determined.
- Company's CEO and Chairman cite her experience as valuable for U.S. expansion and potential FDA approval of DrugSorb™-ATR.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175151/000110465922042785/0001104659-22-042785-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175151/000110465922042785/tm2210684d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-042785

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer